A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies. (2nd December 2018)

• Record Type: Journal Article
• Authors: Zhou, Chuchu; Guo, Chenqi; Li, Wenhao; Zhao, Juan; Yang, Qin; Tan, Tiantian; Wan, Zhuoya; Dong, Jianxia; Song, Xu; Gong, Tao
• Is Part Of: Drug development and industrial pharmacy. Volume 44:Number 12(2018)
• Page Start: 2005
• Page End: 2012
• Publication Date: 2018-12-02
• Subjects: Kolliphor HS15 -- PEGylated liposome -- HS15-LP-HNK -- in vivo studies -- tumor-targeted drug delivery system; Pharmaceutical chemistry -- Periodicals; Pharmaceutical industry -- Periodicals; Drug Industry -- Periodicals; Technology, Pharmaceutical -- Periodicals; 615.05
• DOI: 10.1080/03639045.2018.1506475
• Languages: English
• ISSNs: 0363-9045

Abstract

Abstract: It is necessary to discover a novel antitumor liposome with prolonged circulation time, high efficacy, and low cost. Here, we reported a liposomal honokiol (HNK) prepared with a new type of excipient, Kolliphor HS15, which was termed as HS15-LP-HNK. In addition, we employed PEGylated liposomal honokiol (PEG-LP-HNK) as positive control. The HS15-LP-HNK was prepared by thin-film hydration method. It was near-spherical morphology with an average size of 80.62 ± 0.72 nm (PDI = 0.234 ± 0.007) and a mean zeta potential of −3.91 ± 0.06 mv. In vivo studies exhibited no significant difference between HS15-LP-HNK and PEG-LP-HNK. The pharmacokinetic and biodistribution results showed that HS15-LP-HNK could improve the bioavailability and increase tumor accumulation of honokiol. Furthermore, HS15-LP-HNK could enhance antitumor efficacy of honokiol with low toxicity. In summary, HS15-LP-HNK is promising in tumor targeted drug delivery system.